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splicing enhancers, are required for efficient splicing of Previous reports have identified a pyrimidine-rich the resident exons. In general, exonic splicing enhancers intronic enhancer sequence (S4) downstream of exon appear to activate splicing of the upstream intron 6A as essential for exon 6A 5Ј-splice site recognition. (Lavigueur et al., 1993; Watakabe et al., 1993 ; Xu We show here that preincubation of HeLa cell extracts et al., 1993) . These enhancer sequences contain contiguous with an excess of RNA containing this sequence sperepeats of the motif GARGAR (R ϭ purine). Specific cifically inhibits exon 6A recognition by the splicing binding of SR proteins has been shown for enhancers machinery. Splicing inhibition by an excess of this present in exons of several genes. A direct correlation RNA can be rescued by addition of the SR protein between SR protein binding and activation of splicing has ASF/SF2, but not by the SR proteins SC35 or 9G8.
been established for ASF/SF2 in the case of the growth ASF/SF2 stimulates exon 6A splicing through specific hormone gene (Sun et al., 1993) and SRp40 and SRp55 interaction with the enhancer sequence. Surprisingly, in the case of the troponin T gene (Ramchatesingh et al., SC35 behaves as an inhibitor of exon 6A splicing, 1995). The SR proteins are essential splicing factors since addition to HeLa nuclear extracts of increasing implicated in early steps of the spliceosome formation amounts of the SC35 protein completely abolish the pathway (Krainer et al., 1990; Fu and Maniatis, 1992b) . stimulatory effect of ASF/SF2 on exon 6A splicing. We
In fact, commitment of a pre-mRNA to splicing requires conclude that exon 6A recognition in vitro depends on binding of a specific SR protein to the pre-mRNA (Fu, the ratio of the ASF/SF2 to SC35 SR proteins. Taken 1993; Kohtz et al., 1994; Staknis and Reed, 1994) . Studies together our results suggest that variations in the level of in vitro protein-protein interactions and using the yeast or activity of these proteins could contribute to the two-hybrid system show that the individual RS domains tissue-specific choice of β-tropomyosin exon 6A. In of the SR proteins interact with themselves and with each support of this we show that SR proteins isolated from other (Wu and Maniatis, 1993; Kohtz et al., 1994) . In skeletal muscle tissues are less efficient for exon 6A particular, SC35 and ASF/SF2 have been shown to interact stimulation than SR proteins isolated from HeLa cells. (Fu, 1995) . At least for some of them, alternative splicing activity can be antagonized by The removal of introns from pre-mRNA precursors is an increasing the concentration of the general RNA binding essential and often regulated step in the expression of protein hnRNP A1 (Mayeda et al., 1992 . This has eukaryotic genes. Although there has been much progress led to the idea that some cases of tissue-specific splicing in the last few years in defining the molecular mechanisms may be regulated by simply altering the concentrations or and components involved in constitutive pre-mRNA splicactivities of constitutive pre-mRNA splicing factors. In ing (reviewed in Lamond, 1993; Moore et al., 1993) , the contrast, genetic studies in Drosophila melanogaster have mechanisms by which splice sites are selected remain identified several trans-acting proteins that specifically obscure . Specific recognition of the correct modulate alternative splicing. Regulatory proteins have 5Ј-and 3Ј-splice sites is a fundamental step in the regulation of alternative splicing. The splice sites of most been identified that can either activate or repress the use of specific 3Ј-splice sites involved in sex determination we have examined the ability of an RNA containing exon 6A and downstream intron sequences to specifically (Hodges and Bernstein, 1994) .
Introduction in vivo and in vitro
We have used the chicken β-tropomyosin gene as a interact with factors present in HeLa nuclear extracts, using native gel electrophoresis and binding competition. model to understand the mechanisms underlying the tissuespecific choice of mutually exclusive exons. This gene 32 P-Labeled RNAs were incubated with HeLa nuclear extracts and the resulting complexes were separated on generates a number of different protein isoforms as a result of tissue-specific alternative splicing of its prenative acrylamide gels. As shown in Figure 1 , RNAs containing exon 6A and 200 nt of downstream intron mRNA. It contains three pairs of mutually exclusive exons. In two of these, the exon choice is related to the sequences (712 Pmac) associate with extract proteins leading to retarded mobility. The same RNA molecule use of different promoters or polyadenylation signals. The third pair of exons (6A and 6B) are mutually exclusive lacking the S4 sequence (33 nt) does not form a complex after incubation with HeLa nuclear extracts (Δ4 Pmac, and selected in a tissue-specific manner independent of the promoter or polyadenylation site choice. Exon 6A is deletion of the S4 region). The same result was obtained using RNAs where the 5Ј-(Δ10) or 3Ј-half (Δ11) of the incorporated in fibroblasts and smooth muscle cells, while exon 6B is skeletal muscle specific (Libri et al., 1989a,b) .
S4 sequence was deleted. We have previously shown that both of these deletions (Δ10 and Δ11) weaken the use of Several sequences involved in the choice of exons 6A and 6B have been identified both in vivo and in vitro. Sequences the exon 6A 5Ј-splice site. As a control we analyzed complex formation using an RNA (Δ6 Pmac) where at the 3Ј-end of the intron between exons 6A and 6B and within exon 6B repress the use of the exon 6B 3Ј-splice deletion of 25 nt of intron sequences (Δ6) just upstream of the S4 sequence has no effect on exon 6A splicing site in non-muscle cells (Libri et al., 1990; Gallego et al., 1992) . A pyrimidine-rich region present in the intron efficiency Gallego et al., 1992) . This RNA gives a band of retarded mobility similar to wilddownstream of exon 6A (S4) has been shown to be essential for recognition of the 5Ј-splice site of exon 6A type RNA (Figure 1 , Δ6 Pmac). These results suggest that HeLa nuclear extracts contain a factor(s) that interacts Gallego et al., 1992) .
In this study we sought to identify possible factors that with the 33 nt intronic sequence defined by S4.
To confirm the specificity of this interaction, competition interact with the S4 pyrimidine-rich sequence to facilitate exon 6A splicing. Preincubation of HeLa nuclear extracts experiments using wild-type and mutant RNAs were performed. 32 P-Labeled wild-type RNA (712 Pmac) was with an excess of RNA containing this sequence specifically inhibits exon 6A recognition by the splicing incubated with HeLa nuclear extracts in the presence of different competitor RNAs. Addition of unlabeled wildmachinery, suggesting that a specific factor is being sequestered so as to inhibit splicing. The S4 sequence can type RNA 712 Pmac or Δ6 Pmac reduced complex formation, while addition of Δ4 Pmac had very little effect be replaced by a purine-rich sequence (P3AS, similar to the exonic enhancer sequences) as well as its complementary on complex formation (data not shown). Taken together these results show that the S4 intron sequence specifically polypyrimidine sequence (P3S) with no change in the splicing efficiency of exon 6A. The fact that the purinerecognizes a protein(s) present in HeLa nuclear extracts. rich sequence stimulates exon 6A splicing prompted us to test the possible role of SR proteins in enhancer-dependent Competitor S4 RNA specifically inhibits in vitro splicing of exon 6A activation of exon 6A. ASF/SF2 stimulates exon 6A splicing through specific interaction with the intronic If the binding of a factor(s) to the S4 sequence is essential for exon 6A activation, then addition of an excess of enhancer sequence. In contrast, the protein SC35 counteracts the stimulatory effect of ASF/SF2 on exon 6A unlabeled RNA containing the S4 sequence should specifically inhibit splicing of exon 6A. To test this hyposplicing. These results demonstrate that the ratio of the proteins ASF/SF2 to SC35 influences the splicing efficithesis, we have determined the splicing efficiency of exons 6A-7 in the presence of increasing amounts of ency of exon 6A in vitro. This leads to the hypothesis that variations in the level of these proteins could contribute S4-containing RNA. The reference pre-mRNA used as substrate contains exon 6A, 194 nt of the downstream to exon 6A exclusion in muscle cells. Indeed, we show that SR proteins prepared from skeletal muscle cells intron, 90 nt of the intron upstream of exon 7 and 38 nt of exon 7. The RNA used as competitor (S4 Pmac, 160 nt) support exon 6A splicing poorly as compared with a HeLa SR protein preparation.
is equivalent to 712 Pmac but lacking exon 6A and the first 37 nt of the intron downstream. Addition of an excess of S4 Pmac RNA to the splicing reaction strongly inhibited
Results
the splicing of β-tropomyosin exons 6A-7, as attested by the decrease in accumulation of mRNA and lariat intron A nuclear factor specifically recognizes intron sequences responsible for exon 6A recognition in (Figure 2 , 6A-7). Similar results have been obtained when an RNA containing only the 33 nt of the S4 sequence non-muscle cells We have previously identified a pyrimidine-rich sequence was used as competitor (data not shown). To determine whether this inhibition is specifically associated with the of 33 nt in the intron starting 37 nt downstream of the 5Ј-splice site of exon 6A that is essential for efficient presence of the enhancer sequence, competition experiments were performed on pre-mRNAs lacking the recognition of this splice site (S4; see Figure 3A ). Previous studies support the idea that exon 6A activation by the enhancer sequence (S4). The splicing efficiency of this pre-mRNA (6A-Δ4-7) is 4-to 5-fold lower than that of S4 sequence involves specific interactions with transacting factors present in HeLa cell nuclear extracts (Balvay the wild-type pre-mRNA (6A-7). However, a measurable level of splicing independent of the presence of the et Gallego et al., 1992) . To test this hypothesis Fig. 1 . HeLa cell nuclear extracts contain a factor(s) that specifically binds to the S4 intron sequence. 32 P-Labeled RNAs were incubated with HeLa cell nuclear extracts in splicing buffer for the indicated times and the resulting complexes were separated on a 4% non-denaturing acrylamide gel. For each transcript the first lane corresponds to RNA incubated in the absence of nuclear extract. The incubation times are indicated. A schematic diagram of the different RNAs used in the gel mobility assay are shown on the right. Δ4 is a deletion of the S4 sequence (33 nt). Δ10 and Δ11 are deletions of the 5Ј-and 3Ј-half respectively of the S4 sequence. Δ6 is a deletion of 25 nt of intron sequence just upstream of the S4 sequence.
enhancer sequence was still detected. We expect this level level of splicing than the wild-type transcript ( Figure 3B , 6A-P3AS-7). Replacement of S4 by the pyrimidine-rich of splicing to be unaffected by the competition experiments described above. In fact, addition of the competitor RNA sequence P3S (which is complementary to the P3AS sequence) fully restored splicing efficiency between S4 Pmac had only a limited effect on the splicing efficiency of pre-mRNA lacking the intronic enhancer sequence β-tropomyosin exons 6A and 7 ( Figure 3B , 6A-P3S-7). Similar results have been obtained after transfection of S4 (Figure 2 , 6A-Δ4-7). This result implies that the competitor RNA does not behave as a general inhibitor myoblasts with a DNA containing equivalent changes to the S4 sequence (Balvay et al., personal communication) . of splicing. We have, as well, determined the splicing activity of β-tropomyosin exons 6B-7 (this RNA does not
In contrast, deletion of the S4 sequence (6A-Δ4-7), or replacement of the S4 sequence by the S5 sequence (6A-contain the S4 enhancer sequence) in the presence of the same amounts of competitor S4 Pmac RNA. As shown in S5-7), led to a decrease in splicing efficiency ( Figure 3B ). Splicing efficiency of 6A-Δ4-7 and 6A-S5-7 was reduced Figure 2 (right panel, 6B-7), addition of 1.5 pmol (60-fold molar excess) of S4 Pmac RNA has no effect on 5-fold and 3-fold respectively compared with that of 6A-7. Note that the S5 sequence, which corresponds to the splicing efficiency of β-tropomyosin exons 6B-7. Furthermore, neither human β-globin nor adenovirus prethe intronic 32 nt sequence immediately downstream of the S4 sequence, can be deleted with no effect on exon mRNA splicing efficiency was affected by the presence of RNA competitor S4 Pmac (data not shown). These 6A recognition in vivo . Similar results have been obtained in vitro (Gallego et al., unpublished results suggest that a titratable factor present in HeLa cell nuclear extracts is able to stimulate exon 6A recognition observations). The fact that three different sequences could act as through interaction with the S4 sequence.
enhancers for activation of the β-tropomyosin exon 6A 5Ј-splice site raised the question of whether they are A purine-rich sequence can replace the S4 sequence for exon 6A 5Ј-splice site activation recognized by a common factor. To answer this question, we tested the effect of addition of competitor RNA S4 We asked whether a sequence rich in the GAR elements, characteristic of exonic enhancer sequences, could replace Pmac on the splicing efficiency of pre-mRNAs containing P3AS and P3S as enhancer sequences. The results in the S4 sequence for splicing activity. The nucleotide composition of the sequences used to replace S4 are Figure 3C show that splicing efficiency of both premRNAs (6A-P3AS-7 and 6A-P3S-7) was reduced in the shown in Figure 3A . The results showing the effect of these substitutions on the splicing efficiency of exons presence of an excess of RNA containing the S4 sequence, as attested by the strong decrease in accumulation of the 6A-7 are presented in Figure 3B . Pre-mRNA 6A-P3AS-7, in which the S4 enhancer sequence was substimRNA. However, higher concentrations of competitor RNA (between 20 and 40%) are needed to reach an tuted by a purine-rich sequence, gave a similar or higher The pre-mRNA 6A-Δ4-7 is equivalent to 6A-7 but lacks the 33 nt corresponding to the S4 sequence. The substrate on the right consists of β-tropomyosin exons 6B and 7 and the complete intron between them. Splicing reactions were carried out for 2 h. The products of the reaction were separated on a 7% denaturing polyacrylamide gel. Schematic representation of the splicing reaction substrate, intermediates and products are indicated on the right. Boxes represent exons and lines represent introns. equivalent level of inhibition when compared with the ent enhancer sequences (S4, P3S and P3AS) and the S5 sequence were UV crosslinked in splicing buffer with wild-type pre-mRNA 6A-7 (Figure 2 ). Thus, we conclude that the wild-type enhancer S4 Pmac can titrate a factor(s) purified total SR proteins from HeLa cell extracts (purified as previously described; Zahler et al., 1992) . The results needed for enhancer function of the P3AS as well as P3S sequences. In a similar way, an excess of competitor RNA in Figure 4 show that the three enhancer sequences interact with the SR proteins and especially with the 30 kDa SR containing either the P3S or the P3AS sequence inhibited splicing of exons 6A-7 independent of the nature of the proteins. In contrast, the S5 sequence, which is not able to activate exon 6A 5Ј-splice site recognition, interacts enhancer sequence (data not shown). Therefore, these results suggest that the three enhancer sequences tested poorly with the SR proteins. These results indicate a correlation between enhancer activity and the capacity to interact with a common set of proteins present in HeLa nuclear extracts.
interact with the 30 kDa SR proteins. Of the known SR proteins, ASF/SF2, SC35 and 9G8 (Cavaloc et al., 1994) possess molecular weights of 30 kDa. To determine ASF/SF2 but not SC35 or 9G8 rescues splicing of exon 6A in the presence of an excess of S4 RNA whether this binding was functionally significant, we have analyzed the ability of the recombinant proteins ASF/SF2, The SR proteins have been shown to bind to purinerich enhancer sequences present in the exons of several SC35 and 9G8 (each isolated from baculovirus-infected insect cells) to rescue splicing activity of exons 6A-7 in alternatively spliced genes (Lavigueur et al., 1993; Sun et al., 1993; Heinrichs and Baker, 1995;  Ramchatesingh the presence of the RNA competitor S4 Pmac. The activity of the individual preparations was determined as their et al., 1995; Tacke and Manley, 1995; Wang et al., 1995) . The fact that a purine-rich sequence can replace the S4 capacity to complement a cytoplasmic S100 fraction with a human β-globin splicing substrate. sequence for exon 6A activation led us to ask whether SR proteins participate in enhancer-dependent splicing of
The results in Figure 5 show that addition of the protein ASF/SF2 in the presence of 0.8 pmol competitor β-tropomyosin exon 6A. We initially tested the ability of the different enhancer sequences to bind SR proteins.
RNA S4 Pmac strongly increased the splicing efficiency of pre-mRNAs containing any of the enhancer sequences Uniformly labeled RNAs corresponding to the three differ- Fig. 3 . Two different sequences can replace S4 for exon 6A activation. (A) Diagrammatic representation of the pre-mRNA containing exons 6A and 7. The intron location of the enhancer sequence S4 and its distance to the exon 6A 5Ј-splice site are indicated. The nucleotide composition of the sequences used to replace S4 (P3S, P3AS and S5) are presented at the bottom of the diagram. (B) Splicing efficiency of exons 6A-7 of the S4 mutant pre-mRNAs. The names of the different pre-mRNAs are indicated at the top. 6A-7, wild-type pre-mRNA; 6A-Δ4-7, pre-mRNA lacking the S4 sequence; for pre-mRNAs 6A-P3S-7, 6A-P3AS-7 and 6A-S5-7 sequence S4 was replaced by sequences P3S, P3AS and S5 respectively. Reaction mixtures were incubated under splicing conditions in 60% nuclear extract for the indicated times. The position of the pre-mRNA, products and intermediates of the reaction are indicated on the right. (C) Splicing of mutant pre-mRNAs in the presence of S4 competitor RNA. The nature of the pre-mRNA tested as well as the amount of competitor RNA added to the reaction are indicated at the top. Reaction mixtures were incubated for 2 h under standard splicing conditions with 35% nuclear extract.
( Figure 5 , 6A-7, 6A-P3S-7 and 6A-P3AS-7). However, as expected, addition of ASF/SF2 protein had only a limited effect on the splicing efficiency of a pre-mRNA lacking an enhancer sequence ( Figure 5 , 6A-Δ4-7). Quantification data show that splicing of 6A-Δ4-7 is 27% stimulated after addition of ASF/SF2, while that of 6A-7 is 125% stimulated. Stimulation of 6A-P3S-7 and P3AS-7 pre-mRNAs by ASF/SF2 was roughly the same as that of 6A-7 pre-mRNA. From these results, we suggest that the level of activation observed on 6A-Δ4-7 is most likely associated with the role of the protein ASF/SF2 as a three enhancer sequences, while no binding is observed on the S5 sequence ( Figure 6 ). In contrast, neither the SC35 nor 9G8 proteins are able to rescue splicing of premRNAs containing either of the enhancer sequences (data SC35 inhibits splicing of exon 6A in an enhancer-specific manner not shown). We conclude that the binding of ASF/SF2 to the enhancer intronic sequence downstream of exon 6A
We have tested the capacity of a SR protein preparation to rescue splicing activity between exons 6A and 7 in the is functionally significant and responsible for activation of exon 6A splicing.
presence of the competitor RNA S4 Pmac. Activity of the 6A-7). Addition of 0.6 μg SC35 reduced the splicing efficiency of 6A-7 and 6A-P3S-7 pre-mRNA by 55 and 75% respectively. This result may explain the inability of a total SR protein preparation to rescue splicing of exons 6A-7 in the presence of the P3S enhancer sequence. In contrast, only a limited effect was observed on the splicing efficiency of the pre-mRNA containing the enhancer was specific, we tested the effect on exons 6A-7 splicing of addition of the proteins 9G8 and ASF/SF2 to a HeLa nuclear extract. Addition of equivalent or higher amounts SR proteins was controlled with a β-globin or adenovirus splicing substrate after addition to S100 extract.
of the SR protein 9G8 had no effect on the splicing efficiency of exons 6A-7 (data not shown). In agreement Results presented in Figure 7 indicate that addition of SR proteins can rescue splicing of exons 6A-7 for prewith the results in Figure 5 , addition of ASF/SF2 stimulated splicing of pre-mRNAs containing any of three enhancer mRNAs containing either the wild-type enhancer sequence S4 (Figure 7 , 6A-7) or the purine-rich enhancer P3AS sequences (data not shown). We conclude that the inhibitory effect of SC35 on exons 6A-7 splicing is specific to (Figure 7 , 6A-P3AS-7). As expected, no stimulation of splicing activity for a precursor RNA lacking an enhancer this SR protein and is not a general effect induced by addition to the HeLa nuclear extract of an excess of any sequence (Figure 7 , 6A-Δ4-7) was detected after addition of SR proteins. Surprisingly, splicing of the pre-mRNA SR protein. containing the pyrimidine-rich enhancer sequence P3S was not activated after addition of the SR proteins SC35 antagonizes the positive effect of ASF/SF2 in exon 6A splicing (Figure 7 , 6A-P3S-7). This result is in apparent contradiction to those described above showing that the SR protein
The simplest hypothesis to explain the inhibitory effect of SC35 on the splicing efficiency of exons 6A-7 is ASF/SF2 is able to rescue splicing of exons 6A-7 independent of the nature of the enhancer sequence ( Figure 5) . competition with ASF/SF2 on the enhancer sequence. In order to obtain a functional test for the ability of SC35 to The simplest hypothesis to explain this discrepancy would be the presence in the total SR preparation of a directly counteract the effect of ASF/SF2 on exon 6A activation we prepared HeLa nuclear extracts depleted of protein able to counteract the effect of ASF/SF2 on exon 6A activation. As mentioned above, the three enhancer SR proteins. We used as a SR-depleted HeLa nuclear extract the fraction that precipitates at 65% ammonium sequences UV crosslinked a protein(s) of 30 kDa in a total SR protein preparation. We decided to determine sulfate. This SR-depleted HeLa nuclear extract showed very little activity in supporting splicing of exons 6A-7 whether the 30 kDa SR proteins SC35 and 9G8 could counteract ASF/SF2 for exons 6A-7 splicing. In fact, (Figure 9 , lane 1 for each pre-mRNA). No splicing activity was detected when a human β-globin pre-mRNA was addition of recombinant SC35 protein to the in vitro splicing reaction strongly inhibited splicing of exons used as substrate (data not shown). Addition of SC35 was not able to stimulate splicing of exons 6A-7, whatever 6A-7 for pre-mRNAs containing the P3S enhancer sequence (Figure 8 , 6A-P3S-7) and to a lesser extent that the nature of the enhancer sequence ( Figure 9 , lanes 2 and 3 for each pre-mRNA). However, as expected, splicing containing the wild-type enhancer sequence S4 (Figure 8, Fig. 7 . The SR proteins stimulate exon 6A splicing in an enhancer-specific manner. The pre-mRNA substrates containing an enhancer sequence (6A-7, 6A-P3S-7 and 6A-P3AS-7) or lacking the S4 sequence (6A-Δ4-7) were incubated under standard splicing conditions. The absence or presence of 0.8 pmol competitor RNA (S4 Pmac) is indicated (-or ϩ). The amount of SR proteins from HeLa cells added to each reaction is indicated in μg. After 2 h incubation, splicing products were separated in a 7% denaturing acrylamide gel. The position of the precursor, products and intermediates are shown on the right. of the three pre-mRNAs used as subtrate was stimulated is the mechanism allowing exclusive use of exon 6B . It has been shown that the SR proteins after addition of ASF/SF2 (lane 4 for each pre-mRNA). To answer whether SC35 could directly counteract the are differentially expressed in a variety of cells and tissues (Fu and Maniatis, 1992a; Vellard et al., 1992 ; Zahler splicing stimulatory effect of ASF/SF2, we added increasing amounts of SC35 to the ASF/SF2-containing extract. et al., 1993) . In particular, skeletal muscle tissue SR preparations contain a proportionally lower amount of the The results of this experiment indicate that addition of SC35 has an inhibitory effect on the splicing efficiency 30 kDa proteins compared with the thymus SR proteins . of pre-mRNAs containing either the wild-type enhancer sequence S4 or the P3S enhancer sequence (Figure 9 , We have considered the hypothesis that non-recognition of the intronic enhancer sequence downstream of exon lanes 5-7, 6A-7 and 6A-P3S-7). In contrast, very little effect on the splicing of exons 6A-7 was detected after 6A in skeletal muscle cells may be related to the SR factor content of this tissue. To test this assumption, we addition of equivalent amounts of SC35 for the pre-mRNA containing the P3AS enhancer sequence (Figure 9 , lanes prepared SR proteins from chicken embryo pectoral muscle tissue and compared them with HeLa SR proteins by 5-7, 6A-P3AS-7), which confirmed the results presented in Figure 8 . Addition of 0.4 μg SC35 reduced splicing of SDS-PAGE analysis followed by immunoblotting with mAb 104 or specific antibodies directed against SC35 6A-P3S-7 and 6A-7 by 90 and 75% respectively, while splicing of 6A-P3AS-7 was only reduced by 20%. Taken (αSC35; see Materials and methods). Figure 10A (left panel) shows an mAb 104 immunoblot with an equal together these results strongly suggest that recognition of β-tropomyosin exon 6A depends upon the ratio of ASF/ amount of SR proteins extracted from HeLa cells and skeletal muscle (180 ng). HeLa cells and skeletal muscle SF2 to SC35. These two proteins have an antagonistic effect on intronic enhancer-dependent activation of exhibit a different profile of SR proteins. SRp55 and SRp20 are more abundant in skeletal muscle tissues than β-tropomyosin exon 6A.
in HeLa cells, in contrast to SRp40 and SRp75, which are more abundant in HeLa cells than in muscle tissues. SR proteins prepared from skeletal muscle tissue do not support exon 6A splicing However, for the same amount of SR proteins prepared from HeLa cells or skeletal muscle, the monoclonal Previous results have shown that exon 6A exclusion in myotubes depends upon the presence of an active exon antibody mAb 104 recognizes roughly equivalent amounts of SRp30 proteins. In contrast, the αSC35 immunoblot 6B, suggesting that competition between these two exons ( Figure 10A , right pannel) reveals that 90 ng of skeletal containing exons 5, 6A and 7 in which the 3Ј-splice site of exon 6A had been deleted, allowing only splicing of SR preparation gives a stronger signal than 180 ng of the SR preparation from HeLa cells. Quantitative analysis exon 5 or exons 6A to 7. The results in Figure 10B show that addition of 0.5 μg SR proteins from HeLa cells shows that skeletal SR proteins contain 2.3 times more SC35 protein than HeLa SR proteins, referenced to an activated splicing of exons 5-7, as attested by accumulation of the slower migrating lariat ( Figure 10B , lane 2). equivalent amount of total SRp30 proteins. To test the activity of the two SR protein preparations, substrate preIncreasing the amount of SR proteins to 0.75 μg allowed activation of exons 6A-7 splicing ( Figure 10B , lanes 3-mRNA was incubated in a SR-depleted HeLa nuclear extract. To facilitate the analysis, we used a pre-mRNA 5). As shown in the right panel, addition of SR proteins from skeletal muscle cells supported splicing of exons 5-7 to a level comparable with that of the HeLa cell SR protein preparation. However, no significant stimulation of exons 6A-7 splicing was detected, even after addition of 1.5 μg SR proteins ( Figure 10B, lane 9) . Thus, these results indicate that the SR proteins from muscle cells recognize the intronic enhancer sequence downstream of exon 6A poorly in vitro. This also supports the idea that in muscle cells down-regulation of exon 6A may contribute to its exclusion in this type of cell.
Discussion
Role of ASF/SF2 as a positive regulator of β-tropomyosin exon 6A splicing We have previously identified a splicing enhancer element (S4) in the intron downstream of chicken β-tropomyosin exon 6A as essential for its recognition Gallego et al., 1992) . The purpose of this study was the identification of the factor(s) able to activate exon 6A recognition through binding to the S4 sequence. We show here that the SR protein ASF/SF2 is able to activate the use of exon 6A through specific recognition of the S4 enhancer sequence. This conclusion is supported by the results showing that: (i) addition of ASF/SF2 to the splicing reaction relieved the splicing inhibition generated sequence can be activated through interaction with a SR Splicing of human β-globin was not inhibited after addition of equivalent or higher amounts of SC35 (data not shown).
protein (ASF/SF2). Fig. 9 . SC35 antagonizes enhancer-mediated splicing activation of exon 6A by ASF/SF2. The pre-mRNA subtrates were incubated under splicing conditions with an SR-depleted nuclear extract (fraction precipitated at 65% ammonium sulfate). The indicated amounts of SC35 and/or ASF/SF2 were added to each reaction mixture. Under these conditions, addition of the SC35 protein stimulated splicing of a human β-globin substrate (data not shown). Several intronic splicing enhancer sequences have been troponin T (Ramchatesingh et al., 1995) . It will be interesting to determine whether SR proteins play a general described. Splicing of exon IIIB of the rat fibronectin gene depends on repeats in the downstream intron of the role in the activation of non-purine-rich intronic enhancer sequences. motif UGCAUG (Huh and Hynes, 1994) . Mutation of the six motifs (AU)GGG present in the chicken β-tropomyosin
The involvement of ASF/SF2 in the activation of a pyrimidine-rich enhancer sequence is unexpected. Indeed, intron downstream of exon 6B strongly inhibits splicing of this intron (Sirand-Pugnet et al., 1995) . Interestingly, to date ASF/SF2 has been implicated in the recognition of exonic enhancer sequences rich in purines (Sun et al. , as for the tropomyosin S4 enhancer sequence, the other three intronic enhancers described to date are enriched in 1993; Ramchatesingh et al., 1995) . In fact, in vitro selection of high affinity target sequences for ASF/SF2 pyrimidines and close to the 5Ј-splice site. One is present in the intron downstream of the N1 exon in the c-src gene identified purine-rich sequences (Tacke and Manley, 1995) . One possibility is that ASF/SF2 does not interact with and is essential for its inclusion (Black, 1992) . The second lies downstream of the K-Sam exon of the fibroblast very high affinity with the pyrimidine-rich S4 sequence. In agreement with this, we have indications that recombinant growth factor receptor 2 (Del Gatto and Breathnach, 1995) . The third consists of three intronic elements located ASF/SF2 binds to a S4-containing transcript with a lower affinity than to a transcript containing GAA repeats (data downstream of the 5Ј-splice site of exon 5 of cardiac troponin T, mutations of which prevent exon 5 inclusion not shown). This opens the possibility that the interaction of ASF/SF2 with the target sequence could be mediated in muscle cells (Ryan and Cooper, 1996) . Thus, all these pyrimidine-rich enhancer sequences might constitute a or facilitated by another sequence-specific binding protein.
Although ASF/SF2 is needed for enhancer-dependent new family of intronic enhancers. Only in the case of c-src were the proteins interacting with the enhancer sequence stimulation of exon 6A, we cannot conclude that it is sufficient in itself. Among the factors needed for enhancer investigated. In that case, ASF/SF2 does not seem to be essential for exon N1 recognition (Min et al., 1995) .
recognition, ASF/SF2 could be the only one present in limiting amounts in HeLa nuclear extracts. Supporting However, this does not exclude the possibility that other SR proteins might be involved in the activation process, this hypothesis we have found that ASF/SF2 and the SR proteins fail to activate exon 6A splicing when added to as has been observed for recognition of exon 5 of cardiac an S100 fraction, while human β-globin pre-mRNA is SC35 and splicing activation has not been established (Tian and Maniatis, 1993; Wang et al., 1995) . efficiently spliced (our unpublished observation). Recently, Tacke and Manley (1995) have shown that an element Recently, Kanopka et al. (1996) reported the inhibition of adenovirus IIIa pre-mRNA splicing by SR proteins. containing three copies of a high affinity ASF/SF2 binding site behaves as an exonic splicing enhancer. Consistent
The repressor element located upstream of the IIIa branch site is purine rich. They have shown that ASF/SF2 interacts with our observation, they also showed that ASF/SF2 is needed, though not sufficient, to activate the enhancer in with the repressor element and inhibits splicing of IIIa pre-mRNA. Thus, in contrast to what has been previously a splicing-deficient S100 extract. Therefore, these results indicate that the S100 fraction lacks some activities present thought, this work and our work demonstrate that SR proteins can also be repressors of splicing. Other examples in an SR-depleted nuclear extract (our studies) or in a 20-40% ammonium sulfate fraction of nuclear extract (Tacke of proteins inhibiting splicing by counteracting the role of general splicing factors have been described. Enhancerand Manley, 1995) . Conceivably, these activities are dispensable for basal splicing, but could be absolutely dependent stimulation of bovine growth hormone intron D splicing by ASF/SF2 is antagonized by hnRNP A1 required for the splicing of introns with inherently weak splicing signals. That several factors may be needed to (Sun et al., 1993) . This protein seems to bind with low specificity to the target sequence. Whether hnRNP A1 promote splicing activation has been shown by analyses of the female-specific splicing of Drosophila doublesex competes with ASF/SF2 for overlapping binding sites or hnRNP A1 blocks protein-protein interaction between (dsx) pre-mRNA. The products of the transformer (tra) and transformer-2 (tra-2) genes activate dsx female-ASF/SF2 and other factors remains to be shown. The second example is the work of two independent groups specific splicing by promoting the formation of a splicing enhancer complex which includes the SR proteins and suggesting that binding of PTB to the pyrimidine tract of some introns could repress 3Ј-splice site use by preventing probably other unidentified proteins (Tian and Maniatis, 1993; Amrein et al., 1994; Lynch and Maniatis, 1996) . It binding of the splicing factor U2AF (Lin and Patton, 1995; Singh et al., 1995) . Lastly, the protein Sex-lethal is possible that formation of an enhancer splicing complex constitutes a general mechanism for enhancer-mediated (Sxl) inhibits the use of the non-sex-specific 3Ј-splice site in the first intron of tra pre-mRNA. It has been shown activation of splicing. Further experiments will be required to establish whether the mechanism of β-tropomyosin that Sxl has a higher affinity for the non-sex-specific polypyrimidine tract than the essential splicing factor exon 6A 5Ј-splice site activation involves the formation of a splicing enhancer complex.
U2AF. Furthermore, it was concluded that the inability of Sxl to activate splicing is due to the lack of the splicing effector domain present in U2AF. Thus, addition of the SC35 as an inhibitor of splicing The results in Figure 8 indicate that the general splicing U2AF RS domain to Sxl converts this protein from a splicing repressor to an activator (Valcarcel et al., 1993) . factor SC35 behaves as an inhibitor of β-tropomyosin exon 6A splicing and that its effect is specific, since it
In the example presented here, where SC35 antagonizes the enhancer-dependent splicing effect of ASF/SF2, both depends on the nature of the intronic enhancer sequence. Furthermore, we show that SC35 directly antagonizes proteins contain an RS domain needed for protein-protein interactions. ASF/SF2 contains an RNA recognition motif ASF/SF2 for exon 6A splicing activation (Figure 9 ). These results indicate that SC35, although able to interact with (RRM) and also a divergent repeat of the RRM called the RRMH , which is absent in SC35. It the enhancer sequence, is not able to induce exon 6A splicing activation. In agreement with our observations, it will be interesting to determine whether the presence of this domain could explain the different activities of the has been shown that three copies of a SC35 high affinity binding site failed to function as an exonic enhancer two proteins. sequence (Tacke and Manley, 1995) . Since SC35 binds to the target sequence, it has been suggested that SC35 may Tissue-specific choice of β-tropomyosin exon 6A A complex mechanism is responsible for the tissue-specific be unable to stimulate splicing of a weak 3Ј-splice site by binding to exon sequences. These authors selected target selection of the mutually exclusive exons 6A and 6B in the chicken β-tropomyosin gene. Both in vivo and in vitro sequences in vitro for the proteins ASF/SF2 and SC35. They found that some of these sequences can be recognized analyses have shown that sequences in the 3Ј-half of the intron between these two exons and in exon 6B are by both proteins. It would be interesting to test whether these types of sequences will work as splicing enhancers involved in exon 6B repression in non-muscle cells (GouxPelletan et al., 1990; Libri et al., 1990; Gallego et al. , through specific interaction with ASF/SF2. Since they were selected as sequences also recognized by SC35, it 1992). However, mutations activating exon 6B in nonmuscle cells are not sufficient to induce total exclusion of is tempting to predict splicing inhibition by an excess of this protein. At present, no example of natural enhancer exon 6A in transfected myoblasts and do not lead to exon 6A exclusion in HeLa cell extracts, suggesting that exon activation by SC35 has been reported. Indeed, it has been shown that SC35 is unable to activate enhancer-dependent 6A is also regulated. We have shown here that an SR protein preparation from chicken skeletal muscle tissue splicing for either the last exon of bovine growth hormone or exon 5 of cardiac troponin T pre-mRNAs (Sun et al., does not support exon 6A splicing, while this exon is efficiently recognized by a HeLa cell SR protein prepar-1993; Ramchatesingh et al., 1995) . However, in both cases the lack of activity was associated with an inability of ation ( Figure 10B ). In contrast, both preparations stimulate splicing of exons 5-7 to an equivalent level. Differences SC35 to bind the enhancer element. SC35 has been identified as a constituent of two enhancer splicing comin the relative amounts of individual SR proteins have been found between different cells and tissues (Fu and plexes; however, a direct correlation between binding of sodium metaperiodate for 30 min at 0°C. The hydrazones were formed Maniatis, 1992a; Vellard et al., 1992; Zahler et al., 1993) . HeLa cells nuclear extracts were prepared as described previously ( Figure 10A ). Furthermore, we have shown using specific (Dignam et al., 1983) with the modifications of Abmayr et al. (1988) .
antibodies against SC35 that the ratio of SC35 to ASF/ Splicing reactions were performed as described SF2 is at least 2-fold higher in the skeletal muscle SR et al., 1984) and after enzymatic debranching in HeLa S100 exon 6A exclusion in these types of cells.
fractions (Ruskin and Green, 1985 Sun et al., 1993; Tian and Maniatis, 1993; Ramchatesingh The recombinant 9G8 protein, expressed in baculovirus-infected Sf9
et al., 1995; Tacke and Manley, 1995; Wang et al., 1995) .
cells, was immunopurified as described for the human 9G8 protein
These studies indicate that the SR proteins could stabilize (Cavaloc et al., 1994) . Plasmid pAc-HisSC35 was obtained by insertion complex assembly on the 3Ј-splice site. In contrast, the of an EagI-PstI partial digest of plasmid pB1-HPR5 (a kind gift from J.Soret) into the same restriction sites of the pAcSGhisNT-B vector mechanism of splicing activation by intronic enhancers (Pharmigen) . pVL-HisASF was prepared by the insertion of an EcoRIremains largely obscure. Our study should help in the KpnI fragment from plasmid pDS56-ASF (a kind gift from J.Manley) understanding of this process.
into the pVL1392 vector (InVitrogen). After extraction of the total proteins of Sf9-infected cells, histidine-tagged ASF/SF2 and SC35 were purified on a 1 ml Hitrap chelating column (Pharmacia). Due to their
Materials and methods
histidine tag, recombinant SC35 and ASF/SF2 proteins exhibited a higher molecular weight than SR proteins prepared from HeLa cells and Plasmid constructs skeletal muscle ( Figure 10A ). Protein concentrations were determined All β-tropomyosin clones were derived from a 1.7 kb chicken genomic by the dye binding assay (BioRad) with bovine serum albumin as clone spanning exons 4-7 (Libri et al., 1989b) . Construct 6A-7 contains standard. Activity of the protein preparations was tested by complefragment PvuII-PmacI, which includes exon 6A and 194 bp of the mentation of a S100 extract using the E1A unit of adenovirus 2 and downstream intron, fused to fragment BssHII-HindIII, which includes human β-globin pre-mRNAs as splicing substrates. 37 bp of exon 7 and 90 bp of the upstream intron. Constructs 6A-P3S-7 and 6A-P3AS-7 were derived from plasmid 6A-Δ4-7, which is equiva-SR proteins and immunoblotting lent to 6A-7 but lacks the 33 bp of the S4 sequence. Deletion of the S4 Total SR proteins from HeLa cells and chicken embryo pectoral tissue sequence introduced a PstI site which was used to insert a synthetically were prepared as previously described . SR proteins prepared hybrid oligonucleotide 5Ј-C TTT CTC TTT CTC TCT CCC were resolved by 11.5% SDS-PAGE. Protein gels were electroblotted TCC CTG TCT TTC CCT-3Ј. Insertion in this orientation generated and probed with two antibodies as previously described (Cavaloc et al., the 6A-P3S-7 construct and in the opposite orientation 6A-P3AS-7. 1994): mAb 104 was obtained from the supernatant Construct 6A-S5-7 was derived from plasmid 6A-P3AS-7, in which of a hybridoma culture (ATCC CRL-2067); αSC35 is a monoclonal the P3AS sequence was replaced by a synthetic hybrid oligonucleotide antibody directed against the 15 C-terminal residues of SC35. This 5Ј-CAG CCA CCT CTC CCC TCT CCG CAC TGC TGC CAantibody detects only SC35 and not ASF ( Figure 10A ) or 9G8. 3Ј. Construct 5-6A-7 was made by fusing fragment BamHI-PmacI (containing exon 5, the whole downstream intron, exon 6A and 194 bp RNA mobility shift assays of the downstream intron) to fragment BssHII-HindIII (including 90 bp
The RNA mobility shift assays were performed essentially as described of the intron upstream of exon 7 and 37 bp of exon 7). The 3Ј-splice previously (Konarska and Sharp, 1986) . Capped 32 P-labeled RNAs were site of exon 6A was eliminated by deletion of the fragment PstI-PvuII, synthesized in vitro and purified on acrylamide/urea gels. Binding which includes 150 bp of the intron upstream of exon 6A and the first reactions were performed in splicing buffer with ATP and creatine 13 bp of exon 6A. Deletion of the sequences S6, S10 and S11 has been phosphate, 5 μg tRNA and 1% nuclear extract (25 μl final volume). The described previously . reaction mixtures were preincubated for 10 min at 30°C before addition For UV crosslinking experiments, the synthetic hybrid oligonucleotides of the 32 P-labeled RNA (15 fmol/40 000 c.p.m.). At the indicated times described above were cloned into vector pSP72, to give either RNA P3S the samples were adjusted to 2 mg/ml heparin, 1.5% glycerol, 0.01% or RNA P3AS, or into pGEM 3Z, to give RNA S5 or RNA S4 (sequences bromophenol blue and 0.01% xylene cyanol. The protein-RNA comshown in Figure 3A ). plexes were separated by native gel electrophoresis in 4% acrylamide gels (acrylamide/bis-acrylamide 30:1) using Tris-glycine as the running buffer. The gel was electrophoresed at 4°C at 15 W until the xylene RNA synthesis and splicing reactions Capped RNAs were synthesized in vitro as described previously using cyanol had migrated 13-15 cm and then dried and visualized by autoradiography. SP6 polymerase and [α-32 P] UTP (Ruskin et al., 1984) . All transcripts were further purified by electrophoresis on polyacrylamide/urea gels.
Capped RNAs used as competitors were prepared in a scaled up UV crosslinking experiments Short RNAs were uniformly labeled with [α-32 P]UTP, [α-32 P]CTP and transcription reaction (400 μl) and purified on a Qiagen column (with no carrier). 5Ј-Cap and 3Ј-terminal residues were protected by addition [α-32 P]GTP and purified by polyacrylamide gel electrophoresis. Aliquots of 50 fmol RNA were incubated with 500 ng tRNA, 1 μg bovine serum of biotinamidocaproyl hydrazide (BACH) as follows. RNA (up to 50 μg in 150 μl 3.3 mM sodium acetate, pH 5) was oxidized with 1.5 mM albumin and the indicated amount of total SR proteins or recombinant
